CRON vs BCRX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CRON · Cronos Group$3.04 ▼ 1.30%
BCRX · BioCryst Pharmaceuticals$7.22 ▼ 1.37%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CRON +24.6%
- BCRX +5.7%
Head to head
| Metric | CRON | BCRX |
|---|---|---|
| Price | $3.04 | $7.22 |
| Change today | ▼ 1.30% | ▼ 1.37% |
| Market cap | $1.11B | $1.86B |
| Return, 3 months | -10.9% | -25.4% |
| Return, year to date | +15.6% | -7.4% |
| Return, 1 year | +28.3% | +3.6% |
| P/E (TTM) | 19.0 | – |
| P/B | 1.0 | -4.7 |
| P/E percentile vs own 5y | 88th | 70th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +74.6% | +13.1% |
| Net profit growth (YoY) | -37.1% | +193.9% |
| Gross margin | 46.6% | 97.9% |
| Operating margin | 4.2% | 42.5% |
| Net margin | 28.0% | -37.4% |
| Return on equity | 5.4% | – |
| Analyst target vs. price | +61.2% | +135.5% |
| Analyst buy share | 100% | 67% |
| RSI (14) | 34 | 35 |
| 30-day volatility | 35.5% | 40.4% |
| Max drawdown, 1 year | -26.9% | -35.0% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BCRX is the largest of the group by market value.
- CRON has returned the most over the past year.
- CRON is growing revenue fastest.
- CRON keeps the most profit per dollar of sales.
- CRON has been the calmest stock over the last 30 days.